1502 / 1835
ECHELON-1: Ongoing phase 3 trial of brentuximab
vedotin and AVD vs. ABVD in frontline advanced HL
Schema:
Treatment regimen:
• Brentuximab vedotin + AVD (up to 6 cycles):
- Brentuximab vedotin 1.2 mg/kg IV infusion on
days 1 and 15 of each 28-day cycle
- Doxorubicin 25 mg/m
2
IV infusion on days 1
and 15 of each 28-day cycle
- Vinblastine 6 mg/m
2
IV infusion on 1 days and
15 of each 28-day cycle
- Dacarbazine (DTIC) 375 mg/m
2
on days 1
and 15 of each 28-day cycle
• ABVD (up to 6 cycles):
- Doxorubicin 25 mg/m
2
IV infusion on days 1
and 15 of each 28-day cycle
- Bleomycin 10 units/m
2
IV infusion on Days 1
and 15 of each 28-day cycle
- Vinblastine 6 mg/m
2
IV infusion on 1 days and
15 of each 28-day cycle
- Dacarbazine (DTIC) 375 mg/m
2
on days 1
and 15 of each 28-day cycle
Objectives:
• Primary: PFS
• Secondary:
- Overall survival
- Others: CR rate, safety, EFS, DFS, ORR, DOR,
duration of CR, rate of irradiation for those not in
CR, CR at the end of front-line therapy, rate of
cycle 2 PET negativity, HRQOL, PK,
immunogenicity
PFS = Progression-free Survival, IRF = Independent review facility, EFS = Event-free survival, DFS= Disease-
free survival, DOR= Duration of response, HRQOL= Health-related quality of life, PK= Pharmacokinetics
Younes A, et al. ASCO 2013; Chicago, US (Abstract #TPS8612)